About
GIT Therapeutics is transforming the future of healthcare by decoding oral drug delivery. Its breakthrough platform enables precise, sustained treatment - delivered exactly where and when it’s needed, eliminating variability, reducing side effects, and replacing invasive therapies. We are committed to setting new standards of care for hundreds of millions worldwide, creating a healthier tomorrow through breakthrough innovation.
The company's proprietary TARDIS oral delivery system uniquely targets the digestive system with sustained-release drug therapy to maximize clinical efficacy, minimize side effects, creating a paradigm shift in therapeutic outcomes, unlocking new market potential in precision medicine.
By obtaining targeted, time controlled sustained release therapy, we aim to address critical unmet needs across major multi-billion-dollar markets , including Parkinson’s disease, MS, IBD (Crohn’s, Ulcerative Colitis), GI infections (H. Pylori, CDI), Celiac disease, and Obesity management.
TARDIS drug delivery system is uniquely engineered to be retained in the stomach or the impossible to efficiently target ileocecal valve (ICV) for a predefined time ensuring sustained, localized, & safe medical therapy. This capability addresses a critical challenge in oral drug delivery - the short and unpredictable drug residence time at key GI regions that highly limits efficacy and safety profiles of current drug treatments.
Q&A
- What is GIT Therapeutics' primary focus?
- GIT Therapeutics is focused on redefining the future of oral drug delivery through its breakthrough platform that enables precise, sustained treatment.
- What is the name of GIT Therapeutics' proprietary drug delivery system?
- The company's proprietary system is called TARDIS, an oral delivery system designed to target the digestive system with sustained-release drug therapy.
- Which medical conditions does GIT Therapeutics aim to address with its TARDIS system?
- GIT Therapeutics aims to address critical unmet needs in conditions such as Parkinson’s disease, MS, IBD (Crohn’s, Ulcerative Colitis), GI infections (H. Pylori, CDI), Celiac disease, and Obesity management.
- When was GIT Therapeutics founded?
- GIT Therapeutics was founded in October 2024.
- Where is GIT Therapeutics headquartered?
- GIT Therapeutics is headquartered in Tel Aviv-Yafo, Israel.
- How many employees does GIT Therapeutics currently have?
- GIT Therapeutics has 1-10 employees.
- Who are the co-founders of GIT Therapeutics?
- The co-founders of GIT Therapeutics are Erez Cohn (Co-Founder & CEO), Avshalom Ben Manachem (Co-Founder & CTO), and Ilan Zalit Zalit (Co-founder & CSO).
- What is the current funding stage of GIT Therapeutics?
- GIT Therapeutics is currently in the Pre-Funding stage.
- Does GIT Therapeutics hold any patents?
- Yes, GIT Therapeutics holds 1 patent.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/106481672/ |
Identifiers & details
| Founded | 2024-10 |
|---|---|
| Employees (exact) | 3 |
Radar intelligence
Patents
| EPO | 1 |
|---|